Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Keywords: 3 Kaempferol; 5-Benzylidenethiazolidine-2; AMP-PNP; ATP-binding pocket; ATP-binding site; Adenosine; Bim-8; Cancer; DMAT; Dyrk1A; EMPHASIS; Escherichia coli possess; Fighting Tumor Cell Survival; Glu89; Indolocarbazole; Isogranulatimide; Kenpaullone; Lys67; Moloney leukemia provirus; Myricetin 4; Phosphorylation; Pim Inhibitors; Pim family; Quercetagetin 7; SB 216763; Staurosporine; Streptomyces coelicolor; aminoglycoside; antileukemic activity; antitumor drug targets; aromatic; benzothienopyrimidinone; bisindolylmaleimide; c-Jun N-terminal kinase; carbonitrile; cell-free systems; chemotherapeutic; chemotherapeutic drug(s); cyclin-dependent kinase; cyclopentadienyl; cytotoxic effect; fisetin 2; high throughput screening; highly enhanced; hydrogen-bonding network; hydrophobic interactions; implicates; inconsistent; isoxazole nitrogen; kanamycin; low nanomolar; malignant transformation; mitochondrial fraction; overexpression; pharmakokinetic profile; phenomenon regulated; pro-apoptotic protein; promotes mitochondrial integrity; protein kinases; pyrrazolo; re-sensitized; ruthenium complex; ruthenium stereogenic center; serine/threonine protein kinases; small molecular weight inhibitors; staurosporine; submicromolar; tentative Pim modulators; test systems; transcriptional activity; triazolo
Document Type: Research Article
Publication date: 2010-12-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.